VertexPharma wants to transform the treatment of pain. An upcoming sciatica clinical trial readout will be pivotal.
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Sigma Planning Corp trimmed its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 8.7% during the third quarter, according to its most recent disclosure with the ...
Vertex has reached a key moment because the U.S. Food and Drug Administration (FDA) is reviewing its candidate, suzetrigine, ...
Under Strategic Platform License (SPL) agreements, the company worked with Vertex Pharmaceuticals and CRISPR Therapeutics ... Learn more at maxcyte.com and follow us on X and LinkedIn. MaxCyte ...
The Cas nuclease market is on an upward trajectory, forecasted to grow from $2.75 billion in 2023 to $3.27 billion in 2024, at a CAGR of 18.9%. Key drivers include the rapid advancements in genome ...
We are thrilled to announce that Recursion is setting a new gold standard for the industry with the release of ...
These are the 300 companies whose success goes beyond profits to include employee and customer sentiment, cybersecurity, ...
In addition, we are pleased with the momentum that our partner, Vertex, is building with VX-670 for the potential ... www.entradatx.com, and follow us on LinkedIn. This press release contains ...
Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...
Research and development expense was $15.5 million for the third quarter of 2024, as compared to $7.6 million for the prior ...